The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma (UC) are unclear. We aimed to study the survival impact of single-agent compared with doublet chemotherapy as second-line chemotherapy of advanced UC.
introduction
Rescue of patients with metastatic urothelial cancer (UC) who have failed first-line chemotherapy or who develop a relapse early after perioperative chemotherapy is still problematic. At present, no Food and Drug Administration (FDA)-approved agent is available as a conventional option and vinflunine is the only European Medicines Agency (EMA)-approved drug for these patients [1] . Irrespective of the type of single-agent chemotherapy that is employed as first or later salvage therapy, results are frustratingly poor and there is a desperate need for new agents. Median progression-free (PFS) and overall survival (OS) invariably approximated 3 and 6 months, respectively, and these estimates are currently applied to the design of trials of salvage therapy.
Improvements in the stratification of outcome in the secondline setting have been achieved as well, and validated prognostic grouping systems are available [2] [3] [4] . The same applies to the understanding of the prognostic impact of several additional factors for clinical use. Poor tolerability of chemotherapy in these patients is a major concern and often limits the administration of potentially more active, yet more toxic combination regimens. As a result, the administration of single-agent taxanes ( paclitaxel or docetaxel) or vinflunine are the two equally available options outside of clinical trials. Nonetheless, huge heterogeneity characterizes the available results with second-line chemotherapy and the survival advantage with the use of combination regimens remains substantially unproven.
Modern research strategy in UC should focus on the rational delivery of standard systemic chemotherapy and on the optimal chemobiologic combination or sequence with novel compounds. In order to allow the design of informed clinical trials, it will be of primary importance to identify which are the best results achievable with chemotherapy and, ideally, for which patients. For fit patients who may be administered combination chemotherapy, for example, the benchmark of single-agent chemotherapy might not reflect the best achievable result. Otherwise for the majority of patients for whom tolerability of treatments is a concern due to poor performance status or organ function, the single-agent benchmark may be used.
For these reasons, quantifying the survival differences between single-agent and combination chemotherapy will be a compelling argument for further research. The comparison of single-agent with doublet chemotherapy as second-line chemotherapy for metastatic UC was the objective of the present systematic review and meta-analysis. We focused on the two-drug combination chemotherapy only because the administration of three or more drugs in these patients is quite rare in clinical practice. The hypothesis was that doublet chemotherapy may be recommended as the first option for selected patients given its exhibited efficacy and that drug development in this disease should separate patient categories according to the best deliverable chemotherapy.
patients and methods

search strategy and data abstraction
We carried out a systematic review and meta-analysis in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [5] .
Eligible studies were searched in Medline, EMBASE, and meeting abstracts presented at congresses of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), American Association of Cancer Research (AACR), and Genitourinary Cancers Symposiums.
The following inclusion criteria have been adopted: period of publication between 1990 and 2014, more than 10 patients enrolled, trials/studies reporting data on second-line single-agent or doublet combination chemotherapy. Principal exclusion criteria were overlapping publications, lack of relevant outcome data, studies entirely reporting on the patients treated before 1990, studies reporting on regimens combining more than two drugs, and the use of single-agent or combinations including molecularly targeted therapies. One randomized trial that allowed the crossover between the two arms was included because of the good quality of the reported results [6] . The population, intervention, comparison, and outcome (PICO) strategy was conducted and the following search string was utilized: 'transitional cell carcinoma'/exp OR transitional AND cell AND carcinoma:ab,ti AND 'chemotherapy'/exp OR 'salvage therapy'/exp OR 'single drug dose'/exp OR 'cancer combination chemotherapy'/exp OR 'salvage therapy':ab,ti OR 'combination chemotherapy':ab,ti OR 'single drug dose':ab,ti AND 'clinical effectiveness'/exp OR 'overall survival'/exp OR 'progression free survival'/exp OR 'cancer staging'/exp OR 'toxicity'/exp.
Additional queries with relevant variants and filters have been added up, integrated by the search through the ASCO portal. Search results were independently reviewed by two authors (DR and AN). Full articles were retrieved for further qualitative review.
statistical methods
The primary objective was to compare treatment containing a single-agent versus a doublet combination chemotherapy; descriptive statistics were used to summarize information across all trials according to the treatment group. The primary end points were the objective response rate (ORR), PFS, and OS; the secondary end point was the incidence of acute (grade 3-4) toxicities. PFS was commonly defined as the time from starting treatment until objective tumor progression or death, OS was defined as the time from treatment start to death for any reason, with censoring at the date of last contact for alive patients. For the purposes of this study, time to progression (TTP) was used whenever it was reported instead of PFS since it was judged an acceptable estimator of PFS in the analyzed studies [i.e. overall, there were very few death events due to toxicity or reasons other than disease progression (PD)]. Random-effects models using inverse variance weighting were used to pool trial-level data (median PFS and OS, and ORR or toxicity probability) separately in each treatment arm. We always applied random-effects models because, according to the Q test and I 2 statistic [7] , heterogeneity among the studies was pretty always present (Q statistic, P < 10% and/or I 2 > 25%). The comparisons between treatment arms were performed by random-effects univariable and multivariable models, with adjustment for the percentage of patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥1 and with hepatic metastases; these percentages were modeled as continuous variables using 3-knots restricted cubic splines [8] .
For each study, the standard error (SE) of the median OS or PFS was derived from the respective 95% confidence interval (CI), when reported, or estimated by using a linear regression model in which the response variable was the log(SE) and the covariates were the median OS or PFS (modeled with a 3-knots restricted cubic spline) and the number of patients. Publication bias was evaluated by visually inspecting funnel plots and using Egger's test for bias. Sensitivity analyses were conducted by using different diagnostic measures like externally standardized residuals, DFFITS values, Cook's distances, DFBETAS values, the estimates of τ 2 (estimated amount of total heterogeneity) when each study is removed in turn.
The statistical analyses were carried out using the SAS® and R software (http://www.R project.org; last access 31 July 2015). All tests and CIs were two-sided; tests were considered statistically significant when the corresponding P values were below the 5% threshold.
results
search results
We identified a total of 1477 studies using the search criteria (EMBASE: 633; Medline: 812; EMBASE and Medline: 32), published between 1995 and 2014. Figure 1 outlines the selection process and reasons for study exclusion. Table 1 presents the principal study characteristics and outcomes [6, A summary of the study characteristics is provided in Table 2 . There were four randomized trials, two in both groups, for both of which both arms were included in the doublet chemotherapy group and only one arm for both in the single-agent group. The median sample size of the trials was 45 (range 13-253) for single-agent and 32 (range 11-48) for doublet chemotherapy. Among the single-agent arms of trials, there were three (13.6%) with vinflunine and five (22.7%) with paclitaxel or docetaxel. Among the doublet chemotherapy arms, 20 (83.3%) were taxanecontaining and 4 (16.7%) carboplatin-containing regimens. Only two studies consisted of a cisplatin-based doublet.
Patient-level characteristics were equally distributed between the two groups, except for a nonstatistically significant higher proportion of patients with ECOG-PS 2 in the doublet chemotherapy group [14% (range 0-23. uni-and multivariable meta-analyses for response and survival outcome
The summary of the outcomes in the two groups is provided in Table 3 , together with the principal subgroup analyses. The pooled ORR with single-agents was 14.2% (95% CI 11.1% to 17.9%) (I 2 = 51.50%, P for heterogeneity = 0.002, with 22 arms included, Egger's test, P = 0.153, Figure 2A ; Bellmunt study was influential, likely due to the high precision of estimates [10] ) versus 31.9% (95% CI 27.3% to 36.9%) (I 2 = 38.20%, P for heterogeneity = 0.030, with 24 arms included, Egger's test, P = 0.008, Figure 2B ; no influential studies were identified) with doublets.
The pooled median PFS for the single-agent group was 2.69 months (95% CI 2.25-3.12) (I 2 = 90.23%, P for heterogeneity <0.001, with 18 arms included, Egger's test, P < 0.001, Figure 2C ; no influential studies were identified) and the pooled median PFS for the doublet group was 4.05 months (95% CI 3.54-4.57) (I 2 = 30.87%, P for heterogeneity = 0.017, with 15 arms included, Egger's test, P = 0.001, Figure 2D ; 9 arms of studies were influential because median PFS diverged from others [31, 35, 37, 40, 43, [47] [48] [49] ).
The same trend was seen for the OS end point: the pooled median OS with single agents was 6.98 months (95% CI 6.19-7.78) (I 2 = 68.50%; P for heterogeneity <0.001, with 20 arms included, Egger's test, P = 0.003, Figure 2E ). Akaza study was influential because median OS diverged from others [25] . The pooled median OS in the doublet group was 8.50 months (95% CI 7.35-9.64) (I 2 = 70.04%, P for heterogeneity <0.001, with 23 arms included, Egger's test, P < 0.001, Figure 2F ). No influential studies were identified. Funnel plots of the OS end point for the single-agent and doublet groups are provided as supplementary Figures S1A and B, available at Annals of Oncology online.
Univariable analyses are provided in Table 4 : the difference of median PFS was 1.60 months (95% CI 0.68-2.52, P = 0.001) and the difference of median OS was 1.46 months (95% CI −0.27 to 3.18, P = 0.097) in favor of the doublet chemotherapy.
The results of the multivariable comparative analyses are also supplied in Table 4 . While response and PFS differences were confirmed as statistically significant (P < 0.001 and 0.002, respectively), OS was not (median difference 0.90 months, range −0.74 to 2.54, P = 0.284). When considering only the taxane or vinflunine among the single-agent arms of studies, ORR was consistently significantly different (P < 0.001), but neither PFS (P = 0.134) nor OS (P = 0.547) was significantly different between the single-agent and doublet chemotherapy groups.
We finally ran another multivariable model adjusting for ECOG-PS 2 and visceral metastases, and the comparison between the two groups favored doublet chemotherapy as follows: P < 0.001 for both ORR probability and median PFS, P = 0.080 for median OS.
incidence of acute toxicities in the two groups 
discussion
In this trial-level meta-analysis of second-line chemotherapy for UC, unique to the authors' knowledge and resembling a huge number of patients, we found statistically significant differences in ORR and median PFS favoring the use of two-drug regimens over single-agents. The difference of median OS between the two groups was trending toward an improvement with the use of doublet chemotherapy regimens, but this was not statistically significant. However, when analyzing only the single-agent arms with vinflunine and taxanes ( paclitaxel or docetaxel), which are the most utilized agents or the standard of care (i.e. vinflunine, but only in Europe) outside of clinical trials, the significant difference for ORR was maintained but it was lost for PFS.
First of all, the inherent limitations in running such metaanalyses are to be accounted for when interpreting the results, and the analyses should be taken as exploratory. The majority of included studies were actually single-arm trials, often with a small sample size. Most importantly, the heterogeneity in reporting the outcomes across trials (e.g. median with 95% CI in some cases, median with ranges in others, PFS in some cases and TTP in others, as outlined in Table 1 ) did represent the most challenging issue when pooling the data together. Available literature is limited in regard to performing this type of meta-analyses and principal references have been mostly supplied herein. This is the reason that we have included sensitivity analyses with the aim to identify possible influential studies/treatments that might have accounted for major biases for each end point. The outcomes were consistent throughout these analyses and only one influential arm has been reported for OS. As a further limitation, we were unable to find information on baseline hemoglobin, Lorusso V, 1998
Ponzato P, 1997 It is plausible that a rational administration of doublet chemotherapy to ECOG-PS 0 patients and of single-agents to ECOG-PS 1-2 or at least PS 2 patients, or a larger dataset of randomized trials would have led to more clinically meaningful and statistically significant differences in survival between the two groups.
Taken together, these results might help guiding the design of the next clinical trials in the salvage setting. We have provided the precise pooled estimates of median PFS and OS to be utilized when determining the advantage from adding or comparing a new drug to standard chemotherapy. Although the comparison of median OS was not statistically significant in our study, these benchmark estimates may be considered separately in randomized trials with single-or two-drug combination in the standard therapy arm. This separation might best apply to set the null hypothesis of phase II trials, for which the ORR and PFS improvement (which were both statistically significantly different here between the two groups) are the end points.
Such benchmark estimates are as follows: median PFS of 2.69 months for the single-agents and 4.05 months for the doublet chemotherapy, and median OS of 6.98 months for single-agents and 8.50 months for doublet chemotherapy.
Moving outside of clinical trials, some recommendations could be made for clinical practice on the basis of the present findings. The outcomes with the use of paclitaxel, docetaxel, or vinflunine are unlikely to be significantly improved by adding a second chemotherapeutic drug even when it is feasible. Furthermore, the promising results with the use of the nanoparticle albumin-bound (nab)-paclitaxel lend further confidence to the single-agent strategy. Nab-paclitaxel was investigated as second-line chemotherapy in a Canadian multicenter, singlearm, phase II study [23] . The overall response rate was 27.7% and, most importantly, median OS was 10.8 months despite a high proportion of patients with baseline poor prognostic features. Yet investigating nab-paclitaxel in combination regimens (i.e. with gemcitabine/carboplatin chemotherapy) exhibited significant myelosuppression in the neoadjuvant setting which needs to be carefully addressed if evaluating the same combination in the second line [52] . Major tolerability issues also characterized the efforts of combining vinflunine or pemetrexed with doublet chemotherapy [53] , and consequently investigations of these compounds are mainly conceivable in sequential or maintenance strategies. Substantial uncertainties still lie regarding the use of doublet chemotherapy regimens in the overall population of patients failing platinum-based chemotherapy, but certainly the patient selection is the key to investigate combination chemotherapy further. A few additional studies have been published in [56] . This apparent superiority of taxane-based combination chemotherapy compared with single-agent taxanes was partially confirmed here, in particular for OR and PFS, but not for OS. Taxanes were largely represented in more than 80% of doublet chemotherapy arms. As single agents, the efficacy was clearly overlapping to that of other regimens (as provided in Table 3 ), and this is an indirect evidence corroborating the use of either taxanes or vinflunine as equally active single agents in clinical practice. The present meta-analysis focused on two-drug combinations only, because the use of triple chemotherapy regimens is rarely possible in clinical practice and very few studies are available. Indeed, the possibility to combine two or more chemotherapeutic agents in the salvage therapy for UC may be limited due to poor performance status or comorbidities in most cases. Although we did not find significant differences in the incidence of severe toxicities between the two groups, even after adjusting for some important clinical factors, the critical limitation results from analyzing patients who have been included in clinical trials, who may be quite different from the overall population of advanced and relapsing UC.
Looking at the next steps, the advent of the immune checkpoint inhibitors targeting the programmed death-1/ligand-1 (PD1/PD-L1) is revolutionizing the salvage setting and several active compounds are shedding light on the horizon and will likely be granted FDA and EMA approval for this indication [57] [58] [59] . Pivotal phase III trials are ongoing with these drugs having single-agent chemotherapy in the comparator arm in each case. The same consideration may apply to other promising targeted agents that are in development for molecularly defined cohort of patients [1] . Of course, the association that we will observe between the clinical and biological characteristics of eligible patients will impact the design of the next clinical trials.
The possibility to have potentially active compounds in the salvage setting may lead to an extended OS for at least biologically defined patients. For these patients, the advantage may even be greater with the use of chemobiologic doublets compared with the benchmark of single-agent chemotherapy, although this notion remains to be proved.
In conclusion, in the present meta-analysis comparing singleagent to doublet second-line chemotherapy for UC, we identified a better activity of the latter in terms of ORR and PFS, but we did not find any statistically significant difference in OS. The general recommendation is to continue administering singleagent taxanes or vinflunine outside of clinical trials, although a significant improvement of PFS and the trending-to-significance improvement of OS are suggesting a potentially meaningful benefit from combining agents with proven activity in UC. In addition to the development of novel compounds such as PD1 and PD-L1 inhibitors as single agents, the prospective evaluation of tolerable combinations of chemotherapeutic drugs as well as chemobiologic combinations is rational.
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